Arbutus Biopharma Corp. (NASDAQ: ABUS) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its RNAi therapeutic imdusiran for the treatment of chronic hepatitis B. The designation, awarded on April 15, 2026, recognizes imdusiran as a promising treatment for a serious condition with unmet medical need and may provide the company with more frequent FDA interactions and the possibility of accelerated approval or priority review if the drug meets its clinical milestones.
Imdusiran is a GalNAc‑conjugated RNAi agent that targets all hepatitis B viral antigens. In the IM‑PROVE I Phase 2a trial, functional cure rates were 25% overall and 50% in patients with baseline HBsAg levels below 1,000 IU/mL when combined with interferon. To date, the drug has achieved functional cure in 10 chronic hepatitis B patients across clinical studies, underscoring its potential to move beyond viral suppression toward durable remission.
“We are excited about the potential of imdusiran, which in trials has achieved functional cure for 10 chronic hepatitis B patients to date and allowed many others to live medication‑free, to address significant unmet medical need,” said President and CEO Lindsay Androski. “The FDA grant of Fast Track designation validates imdusiran as an important drug candidate, and we look forward to working collaboratively and closely with the FDA during the remaining stages of the development process.”
The announcement was met with a positive market reaction, as investors highlighted the regulatory milestone and the encouraging early clinical data. Analysts noted that the Fast Track status could accelerate the drug’s development timeline and enhance Arbutus’s competitive position in the emerging functional‑cure HBV space.
Arbutus’s recent settlement with Moderna, which provided a substantial upfront payment and potential future royalties, adds financial flexibility to support the continued development of imdusiran. With the Fast Track designation in place, the company is positioned to pursue accelerated regulatory pathways and to engage in strategic partnerships that could bring the therapy to patients more quickly.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.